Collegium Pharmaceutical Inc (COLL)vsTeva Pharma Industries Ltd ADR (TEVA)
COLL
Collegium Pharmaceutical Inc
$37.80
-3.89%
HEALTHCARE · Cap: $1.11B
TEVA
Teva Pharma Industries Ltd ADR
$35.73
-0.78%
HEALTHCARE · Cap: $41.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 2123% more annual revenue ($17.35B vs $780.57M). TEVA leads profitability with a 9.0% profit margin vs 8.1%. COLL trades at a lower P/E of 19.8x. COLL earns a higher WallStSmart Score of 65/100 (B-).
COLL
Strong Buy65
out of 100
Grade: B-
TEVA
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.2%
Fair Value
$416.48
Current Price
$37.80
$378.68 discount
Margin of Safety
+46.3%
Fair Value
$63.92
Current Price
$35.73
$28.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 30.0%
Every $100 of equity generates 24 in profit
Earnings expanding 31.5% YoY
Earnings expanding 72.2% YoY
Every $100 of equity generates 22 in profit
Areas to Watch
Smaller company, higher risk/reward
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on Operating Margin, Return on Equity, EPS Growth. Revenue growth of 12.9% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, Return on Equity.
Bear Case : COLL
The primary concerns for COLL are Market Cap.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow.
Key Dynamics to Monitor
TEVA carries more volatility with a beta of 0.86 — expect wider price swings.
COLL is growing revenue faster at 12.9% — sustainability is the question.
COLL generates stronger free cash flow (122M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
COLL scores higher overall (65/100 vs 62/100) and 12.9% revenue growth. TEVA offers better value entry with a 46.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?